Exchange: NASDAQ·Updated 07:30 PM EST
IFRX logo

IFRX InflaRx N.V.

$1.02
$0.05
(4.59%)
Today
Closed $1.04
$0.02
(1.92%)
After Hours
EarningsMar 18
Mkt Cap$153.26M
Vol472,107.00

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
40

Bearish Sentiment

How do you feel about IFRX?

Shik79
$IFRX Short term, I’m as frustrated as most here. But this is how this stock moves. The tape since the May peak: 1. Rallies are news-driven and heavy: +14%, +19%, +20% and +10% days, each on 2–6x normal volume. 2. Declines are mostly quiet: 12 of 18 drops of 5%+ came on below-average volume (−7.6% on 284k shares, −5.6% on 221k). That’s missing buyers, not dumping. 3. The CMD was the one real repricing: −26% in 4 days on 10.3M shares, 7x normal on day one. 4. Supply sits at $2.33–2.65, above the $2.00 offering. Every rally culminated there. Outside CMD week, the tape shows no dump, just a drift on thin volume to at or below net cash (~$1.13–1.17/sh). With buyers absent, real news (FDA endpoint alignment, a China deal, aHUS data, a Tavneos ruling) can move this +40% in two weeks, as it did three times this year. Early-Dec 13G/As will show whether the big holders stayed.
12
SeriousDan
1/3 $IFRX CMD Nov 3: what could a best-case AAV design look like? My read of Niels' recent talks (my interpretation, not company guidance). Study: randomized, controlled Ph2b, ideally with blinded BVAS adjudication, first sites early 2027. BVAS is partly subjective (residual symptoms after 3 months), so blinding/adjudication matters a lot for credibility. Primary endpoint: BVAS 0 remission (wk 26) as NON-INFERIORITY vs standard of care. Why: sustained remission at wk 52 can't exceed the wk 26 rate (~70%). Control ~60% vs an ideal drug ~70% = 10 pts max. By his math that needs ~1,000 pts for superiority. NI with an FDA-accepted margin is far smaller.
13
FlowerInTheCellar
$IFRX AAV: Innate Immunity and Kidney Damage An overview published online on October 23, 2026, in Autoimmunity Reviews summarizes evidence on the role of neutrophils, NETs and macrophages in ANCA-associated glomerulonephritis. It highlights C5a as an amplifier of neutrophil activation and inflammatory tissue damage. For IFRX, the paper provides mechanistic context: izicopan blocks C5aR1, while vilobelimab binds directly to C5a. The review contains no new clinical data on izicopan. Its value lies in bringing together a broad body of research into an updated overview; the literature search was updated in June 2026. - Original article: The role of innate immunity in disease initiation and damage control in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis DOI: 10.1016/j.autrev.2026.104200
1
10
MrCompassion
$IFRX Speaking of Montanova, the long-term investor game, kidney health, and catalysts in 2027… PROK: Montanova (fka Suvretta) bought in at ~$9.28 in 2022, nearly tripled its stake at ~$2.21 in 2024, then held 12.3M shares through a drop to $0.59. Sound familiar? IFRX: in since Feb 2021 and has bought into every raise: $5.00 (2021, w/ warrants), $4.25 (2023), $2.00 (2025), $2.00 (2026, ~15M shares), plus open-market adds near $1. Now 22.9M shares. PROK: ~209M Class A shares out. IFRX: ~147M. This fund understands kidney failure and what eGFR says about it. FDA agreed eGFR slope can support accelerated approval for PROK: beat sham by 1.5 mL/min/yr. Phase 2 showed 4.6. Topline Q2 2027 (per company guidance; the registry shows primary completion 12/2029 but that’s the final hard-outcomes endpoint, not the eGFR slope readout that has the potential to enable accelerated approval). What a win would mean: a BLA filing for accelerated approval of
10
Ooil
$IFRX • Market Cap: ~$225M (at $1.53) • Cash: €153.3M (~$166M) runway to end of 2029 • Enterprise Value (EV): ~$59M • AAV Peak Sales (Independent Base Case): $1.65B • Current EV / Peak Sales: ~0.035x Industry average for clinical de-risked assets is 0.3x–0.8x peak sales: • At 0.3x: $4.50 (3x from here) • At 0.5x: $6.75 (4.5x from here) • At 0.8x: $10.10 (6.7x from here) (Calculated on 147M fully diluted shares, cash included) Tavneos was bought out by Amgen for $3.7B on this exact mechanism with severe DILI & CYP3A4 flaws. Izicopan is chemically optimized, hits steady state in <1 wk vs 3 mos, has zero DILI signal, and is backed by Merkel, Jayne, Floege & Barratt. And that doesn't even factor in the newly announced aHUS (2H27 data) or IgAN pipelines. Selling a fully financed pipeline through 2029 down to an EV of $59M just because data hits in 2027/2028 is peak retail impatience meeting short manipulation. Squeeze or value re-rate, the asymmetry here is wild.
11
MrCompassion
$IFRX https://www.sec.gov/Archives/edgar/data/1708688/000114036126041698/0001140361-26-041698-index.html Status quo: €153.3M cash, runway to end of 2029, $65M ATM in place but unused. The real news was the first concrete IgAN plan: an open-label pilot, add-on to standard care, in IgAN and rapidly progressive IgAN, data in 2028. The only realistic non-dilutive (partnering) hope heading into 2028, right as we enter need-for-cash territory.
11
EdV3
$IFRX Hello folks. Let's hope CMD is a bit of a turning point for the company in terms of go forward strategy. I'm curious to see what they unveil. As always, all the potential in the world still exists, but as a cynic myself I am prepared to be disappointed. I will stick to my guns and suggest that when the dust settles, tomorrow will end not being a major market moving catalyst but should rather set the sentiment tone for the upcoming quarters. Don't forget they will also be presenting 3rd quarter financial results and corporate update pre-market so there will definitely be a fair bit of information to digest. Fingers crossed.
11
Monkey82
$IFRX Let's hope for a CSL Vifor partnership announcement. As you may know, CSL Vifor commercialized Tavneos for AAV in multiple regions under a licensing arrangement originating from CCXI, which was later acquired by Amgen in a $3.7B deal. With Tavneos in flux internationally due to safety and efficacy concerns, Izicopan would be a natural partnership fit since Tavneos is one of the most important products linking CSL Vifor directly to the AAV space.
1
8
Yoyo35
$IFRX I see two possible explanations for the November 3 CMD: 1. InflaRx expected to receive FDA meeting minutes before the CMD but got the timing wrong. When the feedback didn’t arrive, they had to choose between postponing the CMD again or presenting without the expected update. I’m not sure which would have been worse for the stock. Or 2. The CMD was always intended to present exactly what we saw. These were simply management’s actual plans.🫩 Regarding the FDA delays, there is a broader context: the agency lost more than 3,000 employees following the 2025 cuts, experienced staff departures, and has struggled to rebuild its workforce. Biotech executives have publicly complained about slower reviews, delayed feedback and regulatory uncertainty. Another concern is that InflaRx management has been very opaque about the extent and status of its interactions with the FDA. They were much more transparent about regulatory interactions during the vilobelimab development process.
10
Sterphanise
$IFRX Don't forget Sirenia Capital Mangement LP with almost 9 Million shares (6,1% of the company). It's almost 109m shares out of 147,2m ~74%
1
6
Monkey82
$IFRX Just confirmed my earlier post regarding 68% institutional ownership as of end Q3 was correct. 100m shares out of 147.2m - 68% it is. Huge positive direction even pre-CMD. Funds generally dont sell within a 6 month window, so not expecting major tute selling in Q4 - its MM’s playing games and getting weak hands to sell.
1
6
Monkey82
$IFRX Based on updated 13F reports, institutional ownership is now up to 68%. A few tutes reduced but one in particular joined the party - Spruce Street Capital - 6m shares. So now 100m shares out of 147.2m shares are owned by tutes. MM's have been successful in shaking out weak hands for the funds. Now we need to see the stock price go up in 2027 where we belong.
9
otcgtc
$IFRX ....new blocktrade 2mio @ $1.10 ,after end of those blocktrades the shareprice is allowed to rise...
8
EdV3
$IFRX There's just no bid....will be below $1 today most likely, if not by end of week 100%. Next strop from there $.55 -$.75 cents if I had to guess. With the additional 75m shares o/s I doubt that 80 cent resistance holds; hence a strong probability of all time lows in the coming weeks.
8
Yoyo35
$IFRX Tomorrow’s InflaRx fireside chat will be moderated by Yatin Suneja, one of the most bullish analysts covering the company. Will he ask the tough questions shareholders actually want answered, challenge management on the disappointing CMD, the FDA pathway, timelines and the lack of concrete progress? Or will he simply give Niels another opportunity to pitch the InflaRx story and sell the dream? Will we get real answers or just more marketing? Stay tuned. The suspense is killing us😎
1
6
Yoyo35
$IFRX All I see is no partnership and a small Phase 2b because they don’t have the budget to do anything bigger… As always, Niels prefers to go it alone. And no accelerated pathway either. I have other important catalysts coming up before the end of the year. I’m wondering whether I should sell my entire position and reinvest in other biotech stocks. Without a partnership, IFRX could stagnate or even drift lower until 2028… On top of that, they’ve once again left a lot of questions unanswered and been vague on many key points. All that’s left now is to wait for the market to open and see how it reacts…
9
Shik79
$IFRX Guggenheim fireside, my takeaways: Seamless Ph2/3 is off. Niels: you can't start a Ph3 without a fixed endpoint, "that’s not possible." FDA wants Ph2 data first. But FDA is open to endpoints beyond BVAS, and several were discussed concretely. "Come back with data" is the plan. "Expedited" now means a Ph2 built to support registration, so the Ph3 can be smaller and shorter. Maybe 6–12 months saved. The lead Ph2 signal is an early drop in proteinuria, which shows up even in small trials. eGFR and renal recovery come next. Enrolment 18 months, China sites could speed it up. Topline ~1H29. Cash "through 2029, still pretty much valid" - so at time of topline we need to raise. Slower than I hoped, but given what the FDA requires, this looks like the practical best path.
8
Dave1961
$IFRX I am so down on this stock right now I could play handball against the curb but still hoping one day again to be shooting hoops with all of you!!
8
EdV3
$IFRX Not that it means anything but some nice little buys at the close and a perfect bounce off the 200.
8
FlowerInTheCellar
$IFRX Sepsis-Associated Kidney Injury: Inflammation, Complement and Precision Medicine - A review published online on October 27, 2026, in Nefrología describes how multiple processes can interact in sepsis, including inflammation, damage to small blood vessels, coagulation disorders, complement activation and changes in cellular metabolism. Since the underlying mechanisms vary between patients, the focus is shifting toward more individualized treatment. However, no specific drug therapy has yet consistently demonstrated improved survival or kidney recovery in sepsis-associated acute kidney injury. In the IFRX context, the review examines biological links between inflammation, complement activation and kidney injury that are also relevant to InflaRx’s broader research landscape. Article: Sepsis-associated acute kidney injury: from biological mechanisms to phenotypes and precision medicine DOI: 10.1016/j.nefro.2026.501700 *Please verify the sources and content independently.
8

Advertisement|Remove ads.